Evolus SEC Filings

Evolus, Inc. reported the results of its Annual Meeting of Stockholders held on June 11, 2026. Stockholders elected Brady Stewart and Vikram Malik as Class II directors, each to serve until the 2029 annual meeting, with Stewart receiving 38,479,626 votes for and Malik 21,310,653 votes for.

Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 51,230,324 votes for. In addition, stockholders approved, on an advisory basis, the compensation of the company’s named executive officers, with 39,350,651 votes for and 336,958 against.

Evolus, Inc. filed a shelf registration (Form S-3) that replaces an expiring registration and registers $195,519,553 of unsold securities from the prior registration and a base prospectus to offer up to $250,000,000 of common stock, preferred stock, debt securities, warrants, units and rights. The prospectus states the company may sell these securities from time to time and that the specific terms will be provided in prospectus supplements. The company notes its common stock trades on Nasdaq under the symbol EOLS and that the last reported sale price was $6.60 per share.

Evolus, Inc. reported first-quarter 2026 results showing modest revenue growth but continuing losses. Total net revenues were $73.1 million, up from $68.5 million a year earlier, driven mainly by Jeuveau and Evolysse product sales. The company posted a net loss of $10.7 million, an improvement from a $18.9 million loss in the prior-year quarter, with loss per share narrowing to $0.16 from $0.30. Cash and cash equivalents were $49.8 million and operating activities used $10.0 million of cash. Evolus’ balance sheet shows total assets of $220.6 million, long-term debt of $156.4 million and a stockholders’ deficit of $28.8 million. Management believes its cash, expected operating cash flows and access to a $30 million asset-based revolving credit facility plus up to $250 million of Pharmakon term loans are sufficient to fund operations for at least the next 12 months. The company highlights ongoing risks including reliance on Jeuveau and Evolysse, significant competition in aesthetics, regulatory dependencies on partners Daewoong and Symatese, required milestone and royalty payments, and a history of accumulated deficits.

Evolus, Inc. reported first quarter 2026 net revenue of $73.1 million, up 7% from a year earlier, driven by $66.4 million of toxin revenue and $6.7 million from injectable HA gels. Gross margin was 66.9%, and adjusted gross margin 68.0%.

The company posted a GAAP operating loss of $6.8 million and net loss of $10.7 million, but achieved positive Adjusted EBITDA of $0.6 million, its second consecutive quarter of positive adjusted profitability. Cash and cash equivalents were $49.8 million as of March 31, 2026.

Evolus reaffirmed 2026 guidance for net revenue of $327–$337 million, adjusted gross margin of 65.5–67.0%, non‑GAAP operating expenses of $210–$216 million, and a low‑ to mid‑single digit Adjusted EBITDA margin. The company also terminated an unused $50 million at‑the‑market equity sales agreement.

Evolus, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 11, 2026 at 8:00 a.m. Pacific Time. Holders of 65,854,751 shares of common stock as of April 14, 2026 may attend online, vote and submit questions via webcast.

Stockholders will elect two Class II directors, Brady Stewart and board chair Vikram Malik, to serve until the 2029 meeting, ratify the appointment of Ernst & Young LLP as independent auditor for 2026, and cast an advisory “say‑on‑pay” vote on compensation for named executive officers. The board recommends voting FOR all three proposals.

The proxy also outlines Evolus’ governance practices, including a majority‑independent board, fully independent key committees, an insider trading policy, a clawback policy tied to accounting restatements, and an enterprise risk management program overseen by the board and its committees. Non‑employee directors receive cash retainers and equity awards in restricted stock units and stock options.

The Vanguard Group amended its Schedule 13G to report that it beneficially owns 0 shares (0%) of Evolus Inc. common stock following an internal realignment. The filing cites the SEC Release No. 34-39538 disaggregation guidance and states certain Vanguard subsidiaries will report separately after the realignment.

The amendment clarifies voting and dispositive powers as 0 and notes the change in reporting structure that led to separate beneficial‑ownership filings by former Vanguard divisions.

Evolus, Inc. officer Rui Avelar reported an open-market sale of 3,119 shares of common stock at a weighted average price of $4.75 per share. According to the filing, these shares were sold under a pre-arranged Rule 10b5-1 trading plan to cover tax withholding obligations from restricted stock unit settlements. Following the sale, Avelar directly holds 427,423 Evolus shares, indicating this was a relatively small, tax-related transaction rather than a large discretionary sale.

Evolus, Inc. director and officer David Moatazedi reported an open-market sale of 13,669 shares of common stock at a weighted average price of $4.7501 per share. According to the filing, the trades were executed under a Rule 10b5-1 trading plan and were required to cover tax withholding obligations from the settlement of restricted stock unit awards. After these transactions, Moatazedi directly holds 604,700 Evolus shares, indicating this was a relatively small, tax-driven adjustment to his overall equity position.